QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.
The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.
Medicago says the side effects were generally mild to moderate and short in duration.
The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.
Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.
The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.
This report by The Canadian Press was first published Nov. 10, 2020.